共 50 条
- [31] Ibrutinib as initial therapy in chronic lymphocytic leukemia: A systematic review and meta-analysisEUROPEAN JOURNAL OF HAEMATOLOGY, 2020, 104 (05) : 512 - 515Molica, StefanoGiannarelli, DianaBaumann, TychoMontserrat, Emili
- [32] The emerging role of ibrutinib in the treatment of chronic lymphocytic leukemiaEXPERT REVIEW OF HEMATOLOGY, 2013, 6 (05) : 543 - 546Molica, Stefano
- [33] A Multicenter Study of Ibrutinib Resistance Development and Intervention with Venetoclax in Patients with Chronic Lymphocytic LeukemiaBLOOD, 2019, 134Rogers, Kerry A.Wei, LaiBhat, Seema A.Jones, DanSeymour, Erlene K.Stephens, Deborah M.Christine, J.Byrd, John C.Woyach, Jennifer
- [34] Evaluation of Cardiovascular Adverse Events Associated With Ibrutinib, Venetoclax and Idelalisib Used in Treatment of Chronic Lymphocytic Leukemia.CIRCULATION, 2018, 138Mahida, HetaviGharia, BharatsinhUgoeke, NeneMaludum, ObioraAsif, ArifCalderon, Dawn
- [35] Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): Focus on Long-Term MRD ResultsBLOOD, 2021, 138 : 3720 - +Jain, NitinKeating, Michael J.Thompson, Philip A.Ferrajoli, AlessandraBurger, Jan A.Borthakur, GautamTakahashi, KoichiEstrov, Zeev E.Sasaki, KojiKadia, Tapan M.Konopleva, MarinaAlvarado, YesidYilmaz, MusaDiNardo, Courtney D.Bose, PrithvirajOhanian, MaroPemmaraju, NaveenJabbour, Elias J.Kanagal-Shamanna, RashmiPatel, KeyurWang, WeiJorgensen, Jeffrey L.Wang, Sa A.Garg, NaveenWang, XuemeiWei, ChongjuanCruz, NicholeAyala, AnaPlunkett, WilliamKantarjian, HagopGandhi, VarshaWierda, William G.
- [36] Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia A Nonrandomized Phase 2 TrialJAMA ONCOLOGY, 2021, 7 (08) : 1213 - 1219Jain, NitinKeating, MichaelThompson, PhilipFerrajoli, AlessandraBurger, Jan A.Borthakur, GautamTakahashi, KoichiEstrov, ZeevSasaki, KojiFowler, NathanKadia, TapanKonopleva, MarinaAlvarado, YesidYilmaz, MusaDiNardo, CourtneyBose, PrithvirajOhanian, MaroPemmaraju, NaveenJabbour, EliasKanagal-Shamanna, RashmiPatel, KeyurWang, WeiJorgensen, JeffreyWang, Sa A.Garg, NaveenWang, XuemeiWei, ChongjuanCruz, NicholeAyala, AnaPlunkett, WilliamKantarjian, HagopGandhi, VarshaWierda, William G.
- [37] Residual disease-guided strategy combining ibrutinib and venetoclax for the treatment of relapsed or refractory chronic lymphocytic leukemiaHEMATOLOGIE, 2022, 28 (04): : 174 - 175Stocker, Nicolas
- [38] Combinatorial Treatment of Chronic Lymphocytic Leukemia with Ibrutinib and Venetoclax Is Superior to Treatment with Single Agents in the TCL1 Mouse ModelBLOOD, 2017, 130Slinger, ErikBalasubramanian, SriramLeverson, Joel D.Eldering, EricKater, Arnon P.
- [39] Phase II Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naive and Relapsed or Refractory Chronic Lymphocytic LeukemiaJOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (31) : 3626 - +Rogers, Kerry A.Huang, YingRuppert, Amy S.Abruzzo, Lynne V.Andersen, Barbara L.Awan, Farrukh T.Bhat, Seema A.Dean, AllisonLucas, MargaretBanks, ChristinGrantier, CaraHeerema, Nyla A.Lozanski, GerardMaddocks, Kami J.Valentine, Thomas R.Weiss, David M.Jones, Jeffrey A.Woyach, Jennifer A.Byrd, John C.
- [40] Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): 4-Year Follow-up DataBLOOD, 2022, 140Jain, NitinKeating, Michael J.Thompson, Philip A.Ferrajoli, AlessandraSenapati, JayastuBurger, Jan A.Borthakur, GautamTakahashi, KoichiEstrov, Zeev E.Konopleva, MarinaSasaki, KojiKadia, Tapan M.Pemmaraju, NaveenDaver, NavalJabbour, EliasDiNardo, Courtney D.Alvarado, YesidYilmaz, MusaBose, PrithvirajOhanian, MaroKanagal-Shamanna, RashmiPatel, KeyurJorgensen, Jeffrey L.Wang, Sa A.Nassar, SamehGarg, NaveenHwang, HyunsooWang, XuemeiCruz, NicholeAyala, AnaPlunkett, WilliamKantarjian, HagopGandhi, VarshaWierda, William G.